Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells.

Espadinha AS, Prouzet-Mauléon V, Claverol S, Lagarde V, Bonneu M, Mahon FX, Cardinaud B.

Oncotarget. 2017 Jul 12;8(44):76174-76188. doi: 10.18632/oncotarget.19192. eCollection 2017 Sep 29.

2.

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.

Gioia R, Trégoat C, Dumas PY, Lagarde V, Prouzet-Mauléon V, Desplat V, Sirvent A, Praloran V, Lippert E, Villacreces A, Leconet W, Robert B, Vigon I, Roche S, Mahon FX, Pasquet JM.

J Pathol. 2015 Sep;237(1):14-24. doi: 10.1002/path.4561. Epub 2015 Jun 4.

PMID:
25965880
3.

Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation.

Bedel A, Pasquet JM, Lippert E, Taillepierre M, Lagarde V, Dabernat S, Dubus P, Charaf L, Beliveau F, de Verneuil H, Richard E, Mahon FX, Moreau-Gaudry F.

PLoS One. 2013 Aug 23;8(8):e71596. doi: 10.1371/journal.pone.0071596. eCollection 2013.

4.

From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.

Bouchet S, Dulucq S, Pasquet JM, Lagarde V, Molimard M, Mahon FX.

Leukemia. 2013 Aug;27(8):1757-9. doi: 10.1038/leu.2013.13. Epub 2013 Jan 16. No abstract available.

PMID:
23392357
5.

Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest.

Drullion C, Lagarde V, Gioia R, Legembre P, Priault M, Cardinaud B, Lippert E, Mahon FX, Pasquet JM.

Leuk Res Treatment. 2012;2012:861301. doi: 10.1155/2012/861301. Epub 2012 Feb 23.

6.

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence.

Drullion C, Trégoat C, Lagarde V, Tan S, Gioia R, Priault M, Djavaheri-Mergny M, Brisson A, Auberger P, Mahon FX, Pasquet JM.

Cell Death Dis. 2012 Aug 16;3:e373. doi: 10.1038/cddis.2012.111.

7.

α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.

Etienne G, Dupouy M, Costaglioli P, Chollet C, Lagarde V, Pasquet JM, Reiffers J, Garbay B, Mahon FX, Turcq B.

Dis Markers. 2011;30(5):221-7. doi: 10.3233/DMA-2011-0777.

8.

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.

Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon FX, Pasquet JM.

Blood. 2011 Aug 25;118(8):2211-21. doi: 10.1182/blood-2010-10-313692. Epub 2011 Jul 5.

PMID:
21730355
9.

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.

Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM.

Cancer Res. 2008 Dec 1;68(23):9809-16. doi: 10.1158/0008-5472.CAN-08-1008.

10.

Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance.

Pocaly M, Lagarde V, Etienne G, Dupouy M, Lapaillerie D, Claverol S, Vilain S, Bonneu M, Turcq B, Mahon FX, Pasquet JM.

Proteomics. 2008 Jun;8(12):2394-406. doi: 10.1002/pmic.200701035.

PMID:
18563733
11.

Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.

Pocaly M, Lagarde V, Etienne G, Ribeil JA, Claverol S, Bonneu M, Moreau-Gaudry F, Guyonnet-Duperat V, Hermine O, Melo JV, Dupouy M, Turcq B, Mahon FX, Pasquet JM.

Leukemia. 2007 Jan;21(1):93-101. Epub 2006 Nov 16.

PMID:
17109025
12.

An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate.

Leguay T, Desplat V, Lagarde V, Marit G, Reiffers J, Mahon FX.

Leukemia. 2005 Sep;19(9):1671-3. No abstract available.

PMID:
15973458
13.

[Cutaneous fistulization of a liver hydatid cyst].

Grigy-Guillaumot C, Yzet T, Flamant M, Bartoli E, Lagarde V, Brazier F, Joly JP, Dupas JL.

Gastroenterol Clin Biol. 2004 Aug-Sep;28(8-9):819-20. French. No abstract available.

14.

Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.

Desplat V, Belloc F, Lagarde V, Boyer C, Melo JV, Reiffers J, Praloran V, Mahon FX.

Cancer. 2005 Jan 1;103(1):102-10.

15.

Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.

Desplat V, Lagarde V, Belloc F, Chollet C, Leguay T, Pasquet JM, Praloran V, Mahon FX.

Cytometry A. 2004 Nov;62(1):35-45.

16.

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV.

Blood. 2003 Mar 15;101(6):2368-73.

PMID:
12609962
17.

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.

Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV.

Leukemia. 2002 Dec;16(12):2349-57.

18.

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

Barthe C, Gharbi MJ, Lagarde V, Chollet C, Cony-Makhoul P, Reiffers J, Goldman JM, Melo JV, Mahon FX.

Br J Haematol. 2002 Oct;119(1):109-11.

PMID:
12358910
19.

Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.

Tabrizi R, Mahon FX, Cony Makhoul P, Lagarde V, Lacombe F, Berthaud P, Melo JV, Reiffers J, Belloc F.

Leukemia. 2002 Jun;16(6):1154-9.

20.

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells.

Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV.

Blood. 2001 Dec 15;98(13):3864-7.

PMID:
11739200
21.

Retroviral coexpression of IFN-alpha and IFN-gamma genes and inhibitory effects in chronic myeloid leukemia cells.

Salesse S, Lagarde V, Ged C, de Verneuil H, Reiffers J, Mahon FX.

J Interferon Cytokine Res. 2000 Jun;20(6):577-87.

PMID:
10888114

Supplemental Content

Loading ...
Support Center